<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23526939</article-id><article-id pub-id-type="pmc">3602457</article-id><article-id pub-id-type="publisher-id">PONE-D-12-33253</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0057240</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Plasma Proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Mathematics</subject><subj-group><subject>Algebra</subject><subj-group><subject>Algebraic Equations</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Modeling</subject></subj-group></subj-group><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Clinical Laboratory Sciences</subject></subj-group></subj-group><subj-group><subject>Nephrology</subject><subj-group><subject>Chronic Kidney Disease</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Multicenter Study of Creatinine- and/or Cystatin C-Based Equations for Estimation of Glomerular Filtration Rates in Chinese Patients with Chronic Kidney Disease</article-title><alt-title alt-title-type="running-head">Creatinine/Cystatin C-Based Equations for eGFR</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Feng</surname><given-names>Jia-fu</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Qiu</surname><given-names>Ling</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xue-mei</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yu-wei</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Xiu-zhi</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Hong-chun</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Xing-min</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yan-peng</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Shu-yan</given-names></name><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Li-qiang</given-names></name><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Quan</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Li-jun</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Hong-zhang</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Fang-cai</given-names></name><xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Duan</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Laboratory Medicine, Mianyang Central Hospital, Mianyang, Sichuan Province, China</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Kidney Internal Medical Department, Mianyang Central Hospital, Mianyang, Sichuan Province, China</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Laboratory Medicine, Peking Union Medical College Hospital, Bejing, China</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Kidney Internal Medical Department, Peking Union Medical College Hospital, Bejing, China</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Laboratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Laboratory Medicine, The First Bethune Hospital of Jilin University, Jilin, Jilin Province, China</addr-line>
</aff><aff id="aff8">
<label>8</label>
<addr-line>Laboratory Department, Nuclear Industrial 416 Hospital, Chengdu, Sichuan Province, China</addr-line>
</aff><aff id="aff9">
<label>9</label>
<addr-line>Laboratory Department, The First People's Hospital of Neijiang, Neijiang, Sichuan Province, China</addr-line>
</aff><aff id="aff10">
<label>10</label>
<addr-line>Kidney Internal Medical Department, The First People's Hospital of Neijiang, Neijiang, Sichuan Province, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Szecsi</surname><given-names>Pal Bela</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Gentofte University Hospital, Denmark</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>jiafufeng@yahoo.com.cn</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The study was supported by Sichuan Maker Biotechnology Co., Ltd., which provided a part of the funds, reagents and quality control materials. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con"><p>Read and approved the final manuscript: All authors. Conceived and designed the experiments: JFF LQ XML. Performed the experiments: XML PZ YQ XMH YPL HCL WX LJX FCZ. Analyzed the data: LQ YWY WX HQ FCZ. Contributed reagents/materials/analysis tools: LZ HCL XZG HZH LQW SYS RD. Wrote the paper: JFF LQ YWY.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>3</month><year>2013</year></pub-date><volume>8</volume><issue>3</issue><elocation-id>e57240</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Feng et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Feng et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Objective</title><p> To establish equations for the estimation of glomerular filtration rates (eGFRs) based on serum creatinine (SCr) and/or serum cystatin C (SCysC) in Chinese patients with chronic kidney disease (CKD), and to compare the new equations with both the reference GFR (rGFR) and the literature equations to evaluate their applicability.</p></sec><sec><title>Methods</title><p> The 788 Chinese CKD patients were randomly divided into two groups, the training group and the testing group, to establish new eGFR-formulas based on serum CysC and to validate the established formulas, respectively. <sup>99m</sup>Tc-DTPA clearance (as the rGFR), serum Cr, and serum CysC were determined for all patients, and GFR was calculated using the Cockcroft-Gault equation (eGFR1), the MDRD formula (eGFR2), the CKD-EPI formulas (eGFR3, eGFR4), and the Chinese eGFR Investigation Collaboration formulas (eGFR5, eGFR6). The accuracy of each eGFR was compared with the rGFR.</p></sec><sec><title>Results</title><p> The training and testing groups' mean GFRs were 50.84&#x000b1;31.36 mL/min/1.73 m<sup>2</sup> and 54.16&#x000b1;29.45 mL/min/1.73 m<sup>2</sup>, respectively. The two newly developed eGFR formulas were fitted using iterative computation: <inline-formula><inline-graphic xlink:href="pone.0057240.e001.jpg"/></inline-formula> and <inline-formula><inline-graphic xlink:href="pone.0057240.e002.jpg"/></inline-formula>. Significant correlation was observed between each eGFR and the rGFR. However, proportional errors and constant errors were observed between rGFR and eGFR1, eGFR2, eGFR4, eGFR5 or eGFR6, and constant errors were observed between eGFR3 and rGFR, as revealed by the Passing &#x00026; Bablok plot analysis. The Bland-Altman analysis illustrated that the 95% limits of agreement of all equations exceeded the previously accepted limits of &#x0003c;60 mL/min &#x02022;1.73 m<sup>2</sup>, except the equations of eGFR7 and eGFR8.</p></sec><sec><title>Conclusion</title><p> The newly developed formulas, eGFR7 and eGFR8, provide precise and accurate GFR estimation using serum CysC detection alone or in combination with serum Cr detection. Differences in detection methods should be carefully considered when choosing literature eGFR equations to avoid misdiagnosis and mistreatment.</p></sec></abstract><funding-group><funding-statement>This work was partially supported by the Science &#x00026; Technology Department of Sichuan Province, China (2009SZ0066) (<ext-link ext-link-type="uri" xlink:href="http://www.scst.gov.cn/info">http://www.scst.gov.cn/info</ext-link>) and Sichuan Maker Biotechnology Co., Ltd. (<ext-link ext-link-type="uri" xlink:href="http://makerbio.company.lookchem.cn/">http://makerbio.company.lookchem.cn/</ext-link>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Chronic kidney disease (CKD) is a serious public health problem worldwide and is usually defined as kidney damage or decreased kidney function with glomerular filtration rates (GFRs) of less than 60 mL/min per 1.73 m<sup>2</sup> for 3 months or longer, regardless of cause <xref rid="pone.0057240-Levey1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0057240-National1" ref-type="bibr">[3]</xref>. Based on GFR, CKD is classified into different stages that require stage-specific management. Therefore, accurate measurement of GFR is critical to evaluate the patient's renal function. Currently, the &#x0201c;gold standard&#x0201d; for GFR determination is to measure the clearance of exogenous substances, such as inulin, iohexol, <sup>51</sup>Cr-EDTA, <sup>99m</sup>Tc-DTPA and <sup>125</sup>I-iothalamate <xref rid="pone.0057240-Florkowski1" ref-type="bibr">[4]</xref>. However, these measurements are not only time-consuming, labor-intensive and expensive but also require the administration of rare substances; thus, these methods are not routinely used <xref rid="pone.0057240-Hojs1" ref-type="bibr">[5]</xref>. Therefore, serum or plasma creatinine levels have become the most commonly used markers for GFR determination because of the simplicity and lower costs of this method <xref rid="pone.0057240-Inker1" ref-type="bibr">[6]</xref>, <xref rid="pone.0057240-Slort1" ref-type="bibr">[7]</xref>. GFR can be calculated based on plasma or serum creatinine using the Cockcroft-Gault or the Modification of Diet in Renal Disease (MDRD) study equations <xref rid="pone.0057240-Slort1" ref-type="bibr">[7]</xref>, <xref rid="pone.0057240-Larsson1" ref-type="bibr">[8]</xref>. However, using plasma or serum creatinine has significant disadvantages, such as the inability to measure renal function correctly when impairment is 50% or less <xref rid="pone.0057240-Slort1" ref-type="bibr">[7]</xref>. Creatinine generation is proportional to muscle mass and related to an individual's age, sex, race and weight <xref rid="pone.0057240-Florkowski1" ref-type="bibr">[4]</xref>, <xref rid="pone.0057240-Slort1" ref-type="bibr">[7]</xref>. As a result, an increase in serum creatinine may not be observed until a substantial decrease in GFR has occurred.</p><p>Cystatin C (CysC) is a cysteine protease inhibitor with a molecular mass of 13 kDa <xref rid="pone.0057240-Salgado1" ref-type="bibr">[9]</xref>. It has been shown that cystatin C is a more sensitive marker of GFR changes than serum creatinine <xref rid="pone.0057240-Roos1" ref-type="bibr">[10]</xref> because its levels are not affected by muscle mass, age, inflammation, fever or exogenous agents <xref rid="pone.0057240-Ferguson1" ref-type="bibr">[11]</xref>. CysC is produced at a constant rate and cleared solely by glomerular filtration <xref rid="pone.0057240-Ferguson1" ref-type="bibr">[11]</xref>, and it can be measured easily with particle-enhanced nephelometric immunoassay (PENIA) <xref rid="pone.0057240-HergetRosenthal1" ref-type="bibr">[12]</xref> or particle-enhanced turbidimetric immunoassay (PETIA) <xref rid="pone.0057240-Voskoboev1" ref-type="bibr">[13]</xref>. Large amount of studies have shown that CysC is superior to SCr in predicting the function of kidney <xref rid="pone.0057240-Liu1" ref-type="bibr">[14]</xref>&#x02013;<xref rid="pone.0057240-Yap1" ref-type="bibr">[18]</xref>. Therefore, CysC has been used as an alternative endogenous serum marker of GFR <xref rid="pone.0057240-Jaisuresh1" ref-type="bibr">[19]</xref>, and many formulas for GFR estimation have been developed based upon serum CysC determination <xref rid="pone.0057240-Robles1" ref-type="bibr">[20]</xref>, <xref rid="pone.0057240-Hojs2" ref-type="bibr">[21]</xref>. However, these formulas were all established based on a small sample and outside of a laboratory, and the &#x0201c;gold standard&#x0201d; measurement of GFR and CysC is also very inconsistent. In addition, these equations have been established in Western populations and they may or may not be suitable for the Chinese population, which requires clinical validation.</p><p>The PETIA-CysC method is becoming more common in clinical practice because of its lower cost and more rapid detection than the PENIA-CysC method <xref rid="pone.0057240-Sohrabian1" ref-type="bibr">[22]</xref>&#x02013;<xref rid="pone.0057240-Hansson1" ref-type="bibr">[25]</xref>. For creatinine measurement, the enzymatic method (enzymatic-Cr) is widely used in the clinical laboratory because of its low chance of cross-contamination and stable results <xref rid="pone.0057240-Greenberg1" ref-type="bibr">[26]</xref>&#x02013;<xref rid="pone.0057240-Wang1" ref-type="bibr">[28]</xref>. In the present study, we applied enzymatic-Cr and PETIA-CysC to determine the creatinine levels and CysC levels, respectively. Following the measurements, we established the eGFR equations based on the levels of CysC and/or serum Cr(SCr) in Chinese CKD patients with multi-center cooperation and evaluated the applicability of these GFR estimating equations.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Subjects</title><p>A total of 788 CKD patients who were referred by nephrologists, diabetologists, cardiologists or general internists were selected from 6 general hospitals between October 2010 and December 2011 in different areas of China, including 421 males (aged 50.4&#x000b1;15.7 years) and 367 females (age,d 51.6&#x000b1;16.6 years). These were 355 patients from North China(Jilin and Beijing, China), 82 patients from Central China(Henan,China), and 351 patients from South China(Mianyang, Chendu and Neijiang, Sichuan, China).All patients met the diagnostic criteria of NKF-KDOQI CKD <xref rid="pone.0057240-Levey1" ref-type="bibr">[1]</xref>, and the following patients were excluded during the selection: (1) patients with acute kidney disease or acute renal insufficiency; (2) dialysis patients; (3) patients with merger edema, pleural effusion, ascites, thyroid disease, or viral hepatitis (carriers were exceptional); (4) malnourished patients (lower than normal protein, blood urea or urine conductivity); (5) disabled patients; and (6) patients using antibacterial drugs, especially trimethoprim and cimetidine.</p><p>A total of 687 cases were chosen randomly for equation development (training group), which included 358 males (aged 50.2&#x000b1;15.6 years) and 329 females (aged 51.5&#x000b1;16.7 years). The remaining 101 cases were assigned to the equation validation (testing group), including 63 males (aged 51.7&#x000b1;16.1 years) and 38 females (aged 52.0&#x000b1;16.1 years).</p><p>The study was approved by the Medical Ethics Committee of Mianyang Central Hospital, Peking Union Medical College Hospital, The First Affiliated Hospital of Zhengzhou University, The First Bethune Hospital of Jilin University, Nuclear Industrial 416 Hospital, or The First people's Hospital of Neijiang, and written informed consent was obtained from all subjects.</p></sec><sec id="s2b"><title>Sample collection</title><p>Blood samples were collected at 8:00 AM. Approximately 5 ml of blood was collected into a BD Vacutainer&#x000ae; SST<sup>TM</sup> II ADVANCE tube (Becton Dickinson, USA) for analysis of CysC and SCr concentrations. After one hour, blood samples were centrifuged at 3000 rpm for 15 min, and serum samples were collected and stored at &#x02212;80&#x000b0;C until analysis within 480 hours.</p></sec><sec id="s2c"><title>Detection methods</title><p>Because of the distribution of subjects in different regions, reference GFR (rGFR) values can only be determined independently in each study institute. In order to make the inter-institutes variance as small as possible, a identical research program among study institutes was established, which including researcher training, <sup>99m</sup>Tc-DTPA drug selection (radiochemical purity greater than 95%, percentage of <sup>99m</sup>Tc-DTPA bound to plasma protein less than 5%), patients' preparation, intravenous injection, blood sampling time point and procedure, regular maintenance of instrument, and radioactivity measurement.</p><p>Reference GFR (rGFR) for each subject was measured when blood samples were collected. In all patients included in the six participating study institutes,<sup>99m</sup>Tc-DTPA clearance was measured as a rGFR. rGFR was measured by the dual plasma sampling method <xref rid="pone.0057240-Ma1" ref-type="bibr">[29]</xref>, standardized by body surface area (BSA), and resulted in the rGFR: rGFR (mL/min per 1.73 m<sup>2</sup>)&#x0200a;=&#x0200a;[Dln (P1/P2)/(T2-T1)] exp {[(T1lnP2)&#x02212;(T2lnP1)]/(T2&#x02212;T1)}&#x000d7;0.93&#x000d7;1.73/BSA, where D is dosage of drug injected. P1 and P2 is plasma activity at T1(first blood sampling) and T2(second blood sampling,), respectively. Units for D, P1 and P2 were cpm/ml, for T1, T2 was minute.Unlike rGFR, SCr and CysC levels were measured in a single laboratory, using a 7600&#x02013;020 Automatic Analyzer (Hitachi, Japan), CysC concentrations was measured by PETIA-CysC method and SCr concentrations were measured by an enzymatic method according to the determination of glycine after enzymatic conversion of creatinine to glycine that can be traced back to IDMS, which kits produced by Sichuan Maker Biotechnology Co., Ltd.(Sichuan, China), but CysC reagents are original equipment manufacture(OEM) products that were obtained from Gentian (Moss, Norway), its calibration can be traced back to ERM-DA471/IFCC. Serum CysC measurements were performed using the following instrument settings: Primary wavelength: 546 nm; Secondary wavelength: 700 nm. Temperature: 37&#x000b0;C; Read points: 19&#x02013;34; sample blank position 16 and spline calibration method. 157 &#x000b5;L assay buffer (reagent 1), and 3.5 &#x000b5;L sample were mixed with 52 &#x000b5;L anti-cystatin C immunoparticles (reagent 2),. The sensitivity of the assay for CysC was 0.03 mg/L. The intra-assay CV was 2.25% (mean, 0.92 mg/L; n&#x0200a;=&#x0200a;20), and the day-to-day CV was 3.18% (mean, 0.68 mg/L; n&#x0200a;=&#x0200a;30). SCr measurements were performed using the following instrument settings: Primary wavelength: 546 nm; Secondary wavelength: 700 nm. Temperature: 37&#x000b0;C; Read points: 17&#x02013;34; sample blank position 16 and linear calibration method. 155 &#x000b5;L enzyme working solution (reagent 1), and 2.0 &#x000b5;L sample were mixed with 26 &#x000b5;L chromogen solution (reagent 2),. The sensitivity of the assay for SCr was 2.40 &#x000b5;mol/L. The intra-assay CV was 1.12% (mean, 135.6 &#x000b5;mol/L; n&#x0200a;=&#x0200a;20), and the day-to-day CV was 1.33% (mean, 382.5 &#x000b5;mol/L; n&#x0200a;=&#x0200a;30).</p></sec><sec id="s2d"><title>eGFR calculation formula</title><p>
<bold>Cockcroft-Gault formula <xref rid="pone.0057240-Cockcroft1" ref-type="bibr">[30]</xref>:</bold>
<disp-formula id="pone.0057240.e003"><graphic xlink:href="pone.0057240.e003.jpg" position="anchor" orientation="portrait"/></disp-formula>
<disp-formula id="pone.0057240.e004"><graphic xlink:href="pone.0057240.e004.jpg" position="anchor" orientation="portrait"/></disp-formula>
</p><p>
<bold>Simplified MDRD formula <xref rid="pone.0057240-Ma2" ref-type="bibr">[31]</xref>:</bold>
<disp-formula id="pone.0057240.e005"><graphic xlink:href="pone.0057240.e005.jpg" position="anchor" orientation="portrait"/></disp-formula>
</p><p>
<bold>MDRD/CKD-EPI formula <xref rid="pone.0057240-Stevens1" ref-type="bibr">[32]</xref>:</bold>
<disp-formula id="pone.0057240.e006"><graphic xlink:href="pone.0057240.e006.jpg" position="anchor" orientation="portrait"/></disp-formula>
<disp-formula id="pone.0057240.e007"><graphic xlink:href="pone.0057240.e007.jpg" position="anchor" orientation="portrait"/></disp-formula>
</p><p>
<bold>eGFR formula of Chinese collaborative group <xref rid="pone.0057240-Ma3" ref-type="bibr">[33]</xref>:</bold>
<disp-formula id="pone.0057240.e008"><graphic xlink:href="pone.0057240.e008.jpg" position="anchor" orientation="portrait"/></disp-formula>
<disp-formula id="pone.0057240.e009"><graphic xlink:href="pone.0057240.e009.jpg" position="anchor" orientation="portrait"/></disp-formula>
</p><p>Unified measurement units were used in the above 6 formulas and the following eGFR7 and eGFR8 formulas to facilitate comparative analyses: Cr: mg/dl; CysC: mg/L; BSA: m<sup>2</sup>; age: years; body weight: kg; height: cm.</p></sec><sec id="s2e"><title>Statistical analyses</title><p>The measurement data are presented as the means&#x000b1;SD, median and range. The differences between genders were estimated by the student t-test for the normal distribution data or the Kolmogorov-Smirnov test for non-normally distribution data.The GFR estimation equations were established based on the Spearman correlation analysis and non-linear regression of parameters including rGFR, CysC, Cr and age. The differences between GFR estimates and rGFR were tested by ANOVA. The consistency was tested by correlation analysis and Bland-Altman analysis, and the previously accepted tolerances was defined as 60 mL/min &#x02022;1.73 m<sup>2</sup>
<xref rid="pone.0057240-Bland1" ref-type="bibr">[34]</xref>. The differences between rGFR and eGFR were analyzed by Passing-Bablok regression analysis. The difference distributions between eGFR and rGFR were performed by Mountain plot. The deviations are shown as the area between the Bland-Altman regression line of difference and the zero difference line. The precision is represented by the coefficient of repeatability (CR). The accuracies are shown as P<sub>15</sub>, P<sub>30</sub>, or P<sub>50</sub>, which represented the proportion of eGFR within 15%, 30%, and 50% of rGFR (&#x000b1;15%, &#x000b1;30%, or &#x000b1;50%). Kappa statistics were used to evaluate the agreement between stages classification from rGFR method and other eGFR methods. The K value can be interpreted as follows: poor agreement (&#x0003c;0.20), fair agreement (0.21&#x02013;0.40), moderate agreement (0.41&#x02013;0.60), good agreement (0.61&#x02013;0.80) and very good agreement (0.81&#x02013;1.0).The PASW Statistics 18.0 (SPSS Inc., Somers, NY, USA) and MedCalc11.5 (MedCalc Software, Mariakerke, Belguim) software products were used for these statistical analyses. Differences with <italic>P</italic>&#x0003c;0.05 are considered statistically significant.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>eGFR curve fitting based on the concentrations of serum CysC and serum Cr</title><p>The basic characteristics of the 788 patients are listed in <xref ref-type="table" rid="pone-0057240-t001">Table 1</xref>. The datasets from the equation development group were tested by Spearman correlation analysis, which revealed negative correlations of rGFR with age, CysC and Cr (r&#x0200a;=&#x0200a;&#x02212;0.212, &#x02212;0.855 and &#x02212;0.809, all <italic>P</italic>&#x0200a;=&#x0200a;0.000). Further non-linear regression fitting was performed for rGFR with age, CysC and Cr, and iterative calculations were used to establish the equation:<disp-formula id="pone.0057240.e010"><graphic xlink:href="pone.0057240.e010.jpg" position="anchor" orientation="portrait"/></disp-formula>
</p><table-wrap id="pone-0057240-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057240.t001</object-id><label>Table 1</label><caption><title>Demographic characteristics of the 788 Chinese CKD patients (up line: mean&#x000b1;SD, down line: median, range).</title></caption><alternatives><graphic id="pone-0057240-t001-1" xlink:href="pone.0057240.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">
<italic>t</italic>/<italic>z</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Training group (n&#x0200a;=&#x0200a;687)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">687</td><td align="left" rowspan="1" colspan="1">358</td><td align="left" rowspan="1" colspan="1">329</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="left" rowspan="1" colspan="1">50.8&#x000b1;16.1 51.0, 19.0&#x02013;87.0</td><td align="left" rowspan="1" colspan="1">50.2&#x000b1;15.6 50.0, 19.0&#x02013;87.0</td><td align="left" rowspan="1" colspan="1">51.5&#x000b1;16.7 52.0, 19.0&#x02013;87.0</td><td align="left" rowspan="1" colspan="1">&#x02212;1.056</td><td align="left" rowspan="1" colspan="1">0.293</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="left" rowspan="1" colspan="1">164.4&#x000b1;7.7 165.0, 148.0&#x02013;184.0</td><td align="left" rowspan="1" colspan="1">168.8&#x000b1;6.6 170.0, 150.5&#x02013;184.0</td><td align="left" rowspan="1" colspan="1">159.7&#x000b1;5.7 160.5, 148.0&#x02013;175.0</td><td align="left" rowspan="1" colspan="1">19.514</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">63.5&#x000b1;11.7 63.0, 32.5&#x02013;110.0</td><td align="left" rowspan="1" colspan="1">68.5&#x000b1;11.5 68.0, 46.0&#x02013;110.5</td><td align="left" rowspan="1" colspan="1">59.2&#x000b1;9.4 57.0, 32.5&#x02013;99.0</td><td align="left" rowspan="1" colspan="1">12.912</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">BSA (m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">1.69&#x000b1;0.17 1.70, 1.18&#x02013;2.28</td><td align="left" rowspan="1" colspan="1">1.78&#x000b1;0.16 1.79, 1.41&#x02013;2.28</td><td align="left" rowspan="1" colspan="1">1.60&#x000b1;0.13 1.59, 1.18&#x02013;2.05</td><td align="left" rowspan="1" colspan="1">16.470</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">rGFR(mL/min&#x000b7;1.73 m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">50.84&#x000b1;31.36 44.19, 3.51,166.00</td><td align="left" rowspan="1" colspan="1">50.38&#x000b1;30.26 45.23, 3.51,147.91</td><td align="left" rowspan="1" colspan="1">51.33&#x000b1;32.56 43.50, 3.95,166.00</td><td align="left" rowspan="1" colspan="1">0.597</td><td align="left" rowspan="1" colspan="1">0.868</td></tr><tr><td align="left" rowspan="1" colspan="1">CysC (mg/L)</td><td align="left" rowspan="1" colspan="1">2.31&#x000b1;1.44 1.88, 0.59&#x02013;8.62</td><td align="left" rowspan="1" colspan="1">2.39&#x000b1;1.50 1.95, 0.59&#x02013;8.62</td><td align="left" rowspan="1" colspan="1">2.22&#x000b1;1.37 1.80, 0.60&#x02013;7.44</td><td align="left" rowspan="1" colspan="1">&#x02212;1.056</td><td align="left" rowspan="1" colspan="1">0.215</td></tr><tr><td align="left" rowspan="1" colspan="1">Cr(mg/dl)</td><td align="left" rowspan="1" colspan="1">2.78&#x000b1;2.78 1.73, 0.40&#x02013;19.77</td><td align="left" rowspan="1" colspan="1">2.94&#x000b1;2.79 1.84, 0.46&#x02013;19.77</td><td align="left" rowspan="1" colspan="1">2.60&#x000b1;2.78 1.69, 0.40&#x02013;15.06</td><td align="left" rowspan="1" colspan="1">&#x02212;1.585</td><td align="left" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" rowspan="1" colspan="1">Testing group (n&#x0200a;=&#x0200a;101)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="left" rowspan="1" colspan="1">51.8&#x000b1;16.0 51.0, 22.0&#x02013;86.0</td><td align="left" rowspan="1" colspan="1">51.7&#x000b1;16.1 49.0, 22.0,86.0</td><td align="left" rowspan="1" colspan="1">52.0&#x000b1;16.1 56.5, 25.0,84.0</td><td align="left" rowspan="1" colspan="1">&#x02212;0.101</td><td align="left" rowspan="1" colspan="1">0.920</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="left" rowspan="1" colspan="1">165.9&#x000b1;8.7 165.5, 150.0&#x02013;182.0</td><td align="left" rowspan="1" colspan="1">170.0&#x000b1;7.5 170.0, 153.5&#x02013;182.0</td><td align="left" rowspan="1" colspan="1">159.1&#x000b1;5.6 159.5, 150.0&#x02013;174.0</td><td align="left" rowspan="1" colspan="1">8.331</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">65.6&#x000b1;14.0 63.0, 41.5&#x02013;108.0</td><td align="left" rowspan="1" colspan="1">70.9&#x000b1;14.0 72.5, 47.0&#x02013;108.0</td><td align="left" rowspan="1" colspan="1">56.8&#x000b1;8.9 55.0, 41.5&#x02013;86.5</td><td align="left" rowspan="1" colspan="1">6.184</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">BSA (m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">1.72&#x000b1;0.21 1.72, 1.34&#x02013;2.27</td><td align="left" rowspan="1" colspan="1">1.81&#x000b1;0.19 1.82, 1.47&#x02013;2.27</td><td align="left" rowspan="1" colspan="1">1.58&#x000b1;0.12 1.56, 1.34&#x02013;1.88</td><td align="left" rowspan="1" colspan="1">7.517</td><td align="left" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" rowspan="1" colspan="1">rGFR(mL/min&#x000b7;1.73 m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">54.16&#x000b1;29.45 47.85, 10.49&#x02013;148.12</td><td align="left" rowspan="1" colspan="1">55.02&#x000b1;30.93 48.51, 10.49&#x02013;148.12</td><td align="left" rowspan="1" colspan="1">52.73&#x000b1;27.16 44.52, 15.34&#x02013;139.43</td><td align="left" rowspan="1" colspan="1">&#x02212;0.284</td><td align="left" rowspan="1" colspan="1">0.776</td></tr><tr><td align="left" rowspan="1" colspan="1">CysC (mg/L)</td><td align="left" rowspan="1" colspan="1">2.13&#x000b1;1.41 1.79, 0.66&#x02013;7.22</td><td align="left" rowspan="1" colspan="1">2.30&#x000b1;1.55 1.85, 0.66&#x02013;7.22</td><td align="left" rowspan="1" colspan="1">1.85&#x000b1;1.09 1.74, 0.76&#x02013;6.39</td><td align="left" rowspan="1" colspan="1">&#x02212;0.964</td><td align="left" rowspan="1" colspan="1">0.335</td></tr><tr><td align="left" rowspan="1" colspan="1">Cr (mg/dl)</td><td align="left" rowspan="1" colspan="1">2.39&#x000b1;2.86 1.56, 0.48&#x02013;23.34</td><td align="left" rowspan="1" colspan="1">2.46&#x000b1;2.25 1.63, 0.52&#x02013;20.46</td><td align="left" rowspan="1" colspan="1">2.28&#x000b1;3.69 1.30, 0.48&#x02013;23.34</td><td align="left" rowspan="1" colspan="1">&#x02212;1.157</td><td align="left" rowspan="1" colspan="1">0.247</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Note: training group <italic>vs.</italic> testing group; all measured indicators had <italic>P</italic>&#x0003e;0.05 (<italic>t</italic> represents t values of the student <italic>t</italic>-test. *<italic>z</italic> represents z values of Kolmogorov-Smirnov test.)</p></fn></table-wrap-foot></table-wrap><p>In addition, the non-linear regression equation of rGFR was established using the CysC single index:<disp-formula id="pone.0057240.e011"><graphic xlink:href="pone.0057240.e011.jpg" position="anchor" orientation="portrait"/></disp-formula>
</p></sec><sec id="s3b"><title>Analysis of the differences between the rGFR and eGFR values estimated by the equations</title><p>The aforementioned 8 equations were used to calculate the eGFRs of the 101 cases in the testing group, which were compared to the rGFR using ANOVA (<xref ref-type="table" rid="pone-0057240-t002">Table 2</xref>). The calculated eGFR values were highly correlated (<italic>P</italic>&#x0200a;=&#x0200a;0.000) with, but not significantly different (F&#x0200a;=&#x0200a;0.812, <italic>P</italic>&#x0200a;=&#x0200a;0.592) from, the rGFR values. Further Passing &#x00026; Bablok analysis revealed that each eGFR value had no apparent linear deviation from the rGFR values (all <italic>P</italic>&#x0003e;0.05). However, among the eGFR values, eGFR1, eGFR2, eGFR4 and eGFR5 all showed significant proportional differences (the 95% CI of slopes did not include B&#x0200a;=&#x0200a;1) and significant constant differences (the 95% CI of intercepts did not include A&#x0200a;=&#x0200a;0) with eGFR6 (<xref ref-type="fig" rid="pone-0057240-g001">Fig 1</xref>-A, B, D-F); eGFR2 showed the most significant errors of both types (a&#x0200a;=&#x0200a;&#x02212;21.267, b&#x0200a;=&#x0200a;1.487), and eGFR3 also showed a highly significant constant error (<xref ref-type="fig" rid="pone-0057240-g001">Fig 1</xref>-C). Only two new equations of the eight did not show significant differences in the proportional errors and the constant errors.</p><fig id="pone-0057240-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057240.g001</object-id><label>Figure 1</label><caption><title>Passing-Bablok plot to analyze and compare eGFR with rGFR.</title><p>(a: 95% confidence interval for the intercept; b: 95% confidence interval for the slope; RSD: residual standard deviation; Cusum test, all <italic>P</italic>&#x0003e;0.05)</p></caption><graphic xlink:href="pone.0057240.g001"/></fig><table-wrap id="pone-0057240-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057240.t002</object-id><label>Table 2</label><caption><title>Overall limits of agreement between eGFR and rGFR (n&#x0200a;=&#x0200a;101).</title></caption><alternatives><graphic id="pone-0057240-t002-2" xlink:href="pone.0057240.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mean&#x000b1;SD</td><td colspan="2" align="left" rowspan="1">correlation analysis</td><td colspan="4" align="left" rowspan="1">Bland-Altman analysis</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>r</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td><td align="left" rowspan="1" colspan="1">Mean differences</td><td align="left" rowspan="1" colspan="1">95% AL</td><td align="left" rowspan="1" colspan="1">acceptable limits*</td><td align="left" rowspan="1" colspan="1">Out of limitsn (%)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rGFR</td><td align="left" rowspan="1" colspan="1">54.16&#x000b1;29.45</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR1</td><td align="left" rowspan="1" colspan="1">56.60&#x000b1;29.70</td><td align="left" rowspan="1" colspan="1">0.7734</td><td align="left" rowspan="1" colspan="1">0.0000</td><td align="left" rowspan="1" colspan="1">&#x02212;2.4</td><td align="left" rowspan="1" colspan="1">&#x02212;51.8&#x02013;46.9</td><td align="left" rowspan="1" colspan="1">98.7</td><td align="left" rowspan="1" colspan="1">6(5.94)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR2</td><td align="left" rowspan="1" colspan="1">58.21&#x000b1;44.50</td><td align="left" rowspan="1" colspan="1">0.7774</td><td align="left" rowspan="1" colspan="1">0.0000</td><td align="left" rowspan="1" colspan="1">&#x02212;4.1</td><td align="left" rowspan="1" colspan="1">&#x02212;59.8&#x02013;51.7</td><td align="left" rowspan="1" colspan="1">111.5</td><td align="left" rowspan="1" colspan="1">4(3.96)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR3</td><td align="left" rowspan="1" colspan="1">48.44&#x000b1;&#x000b1;30.04</td><td align="left" rowspan="1" colspan="1">0.8600</td><td align="left" rowspan="1" colspan="1">0.0000</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">&#x02212;25.2&#x02013;36.6</td><td align="left" rowspan="1" colspan="1">61.8</td><td align="left" rowspan="1" colspan="1">5(4.95)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR4</td><td align="left" rowspan="1" colspan="1">51.00&#x000b1;35.10</td><td align="left" rowspan="1" colspan="1">0.8510</td><td align="left" rowspan="1" colspan="1">0.0000</td><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">&#x02212;33.0&#x02013;39.3</td><td align="left" rowspan="1" colspan="1">72.3</td><td align="left" rowspan="1" colspan="1">6(5.94)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR5</td><td align="left" rowspan="1" colspan="1">55.06&#x000b1;32.68</td><td align="left" rowspan="1" colspan="1">0.8600</td><td align="left" rowspan="1" colspan="1">0.0000</td><td align="left" rowspan="1" colspan="1">&#x02212;0.9</td><td align="left" rowspan="1" colspan="1">&#x02212;33.7&#x02013;31.9</td><td align="left" rowspan="1" colspan="1">65.6</td><td align="left" rowspan="1" colspan="1">5(4.95)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR6</td><td align="left" rowspan="1" colspan="1">56.96&#x000b1;39.07</td><td align="left" rowspan="1" colspan="1">0.8556</td><td align="left" rowspan="1" colspan="1">0.0000</td><td align="left" rowspan="1" colspan="1">&#x02212;2.8</td><td align="left" rowspan="1" colspan="1">&#x02212;43.2&#x02013;37.6</td><td align="left" rowspan="1" colspan="1">80.8</td><td align="left" rowspan="1" colspan="1">5(4.95)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR7</td><td align="left" rowspan="1" colspan="1">54.47&#x000b1;28.06</td><td align="left" rowspan="1" colspan="1">0.8729</td><td align="left" rowspan="1" colspan="1">0.0000</td><td align="left" rowspan="1" colspan="1">&#x02212;0.3</td><td align="left" rowspan="1" colspan="1">&#x02212;28.8&#x02013;28.2</td><td align="left" rowspan="1" colspan="1">57.0</td><td align="left" rowspan="1" colspan="1">7(6.93)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR8</td><td align="left" rowspan="1" colspan="1">52.59&#x000b1;27.07</td><td align="left" rowspan="1" colspan="1">0.8591</td><td align="left" rowspan="1" colspan="1">0.0000</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">&#x02212;28.2&#x02013;31.3</td><td align="left" rowspan="1" colspan="1">59.5</td><td align="left" rowspan="1" colspan="1">7(6.93)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>Note: Units are mL/min&#x000b7;1.73 m<sup>2</sup>; 95% AL, 95% agreement limits. *Acceptable tolerance for the difference between rGFR and eGFR was defined as 60 mL/min/1.73 m<sup>2</sup>. <italic>r</italic> is the Person's correlation coefficient between eGFR and rGFR.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Consistency analysis of the estimated eGFR values and the rGFR values</title><p>As shown in <xref ref-type="table" rid="pone-0057240-t003">Table 3</xref>, when the eGFR values were compared with the rGFR values, the most significant deviation was observed for eGFR2 (<xref ref-type="fig" rid="pone-0057240-g002">Figure 2</xref>-B, 3036 arbitrary units), followed by eGFR1 (<xref ref-type="fig" rid="pone-0057240-g002">Fig. 2</xref>-A, 2045 arbitrary units) and eGFR6 (<xref ref-type="fig" rid="pone-0057240-g002">Figure 2</xref>-C, 1435 arbitrary units). The deviations of the other 5 eGFR equations were similar to each other, and eGFR7 showed the smallest deviation (<xref ref-type="fig" rid="pone-0057240-g002">Figure 2D</xref>, 367 arbitrary units).</p><fig id="pone-0057240-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057240.g002</object-id><label>Figure 2</label><caption><title>Altman-Bland plot: comparison between eGFR and rGFR (n&#x0200a;=&#x0200a;101).</title></caption><graphic xlink:href="pone.0057240.g002"/></fig><table-wrap id="pone-0057240-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057240.t003</object-id><label>Table 3</label><caption><title>Bias, precision and accuracy of eGFR compared with rGFR (n&#x0200a;=&#x0200a;101).</title></caption><alternatives><graphic id="pone-0057240-t003-3" xlink:href="pone.0057240.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Bias<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">CR** mL/min&#x000b7;1.73 m<sup>2</sup>
</td><td colspan="3" align="left" rowspan="1">Accuracy (%)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P<sub>15</sub>
</td><td align="left" rowspan="1" colspan="1">P<sub>30</sub>
</td><td align="left" rowspan="1" colspan="1">P<sub>50</sub>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">eGFR1</td><td align="left" rowspan="1" colspan="1">2045</td><td align="left" rowspan="1" colspan="1">49.3</td><td align="left" rowspan="1" colspan="1">36.63</td><td align="left" rowspan="1" colspan="1">55.45<sup>a,d</sup>
</td><td align="left" rowspan="1" colspan="1">77.23<sup>a,c</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR2</td><td align="left" rowspan="1" colspan="1">3036</td><td align="left" rowspan="1" colspan="1">55.8</td><td align="left" rowspan="1" colspan="1">23.76<sup>a,c</sup>
</td><td align="left" rowspan="1" colspan="1">43.56<sup>a,c</sup>
</td><td align="left" rowspan="1" colspan="1">73.27<sup>a,c</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR3</td><td align="left" rowspan="1" colspan="1">628</td><td align="left" rowspan="1" colspan="1">30.9</td><td align="left" rowspan="1" colspan="1">34.65</td><td align="left" rowspan="1" colspan="1">63.37</td><td align="left" rowspan="1" colspan="1">86.14<sup>b</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR4</td><td align="left" rowspan="1" colspan="1">681</td><td align="left" rowspan="1" colspan="1">36.1</td><td align="left" rowspan="1" colspan="1">36.63</td><td align="left" rowspan="1" colspan="1">63.37</td><td align="left" rowspan="1" colspan="1">81.19<sup>a,d</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR5</td><td align="left" rowspan="1" colspan="1">490</td><td align="left" rowspan="1" colspan="1">32.8</td><td align="left" rowspan="1" colspan="1">39.60</td><td align="left" rowspan="1" colspan="1">65.35</td><td align="left" rowspan="1" colspan="1">89.11</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR6</td><td align="left" rowspan="1" colspan="1">1435</td><td align="left" rowspan="1" colspan="1">40.4</td><td align="left" rowspan="1" colspan="1">31.68</td><td align="left" rowspan="1" colspan="1">59.41<sup>b</sup>
</td><td align="left" rowspan="1" colspan="1">82.18<sup>a,d</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR7</td><td align="left" rowspan="1" colspan="1">367</td><td align="left" rowspan="1" colspan="1">28.5</td><td align="left" rowspan="1" colspan="1">41.58</td><td align="left" rowspan="1" colspan="1">74.26</td><td align="left" rowspan="1" colspan="1">95.05</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR8</td><td align="left" rowspan="1" colspan="1">377</td><td align="left" rowspan="1" colspan="1">29.7</td><td align="left" rowspan="1" colspan="1">41.58</td><td align="left" rowspan="1" colspan="1">72.28</td><td align="left" rowspan="1" colspan="1">93.07</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x003c7;</italic>
<sup>2</sup>
</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">10.812</td><td align="left" rowspan="1" colspan="1">28.341</td><td align="left" rowspan="1" colspan="1">31.399</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">0.147</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">0.000</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label>*</label><p>Bias, the area between the Bland-Altman regression line and the zero difference line; arbitrary unit, i.e., (mL/min&#x000b7;1.73 m<sup>2</sup>)<sup>2</sup>. **CR, Coefficient of Repeatability, equal to the difference between the mean difference and the 95% upper limit of agreement. a: <italic>vs.</italic> eGFR7, by Pearson <italic>&#x003c7;</italic>
<sup>2</sup> test, <italic>P</italic>&#x0003c;0.01: b: <italic>vs</italic>. eGFR7, by Pearson <italic>&#x003c7;</italic>
<sup>2</sup> test, <italic>P</italic>&#x0003c;0.05; c: <italic>vs.</italic> eGFR8, by Pearson <italic>&#x003c7;</italic>
<sup>2</sup> test, <italic>P</italic>&#x0003c;0.01; d: <italic>vs.</italic> eGFR8, by Pearson <italic>&#x003c7;</italic>
<sup>2</sup> test, <italic>P</italic>&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap><p>The performed accuracy showed significant differences in P<sub>30</sub> and P<sub>50</sub> among various eGFR equations (&#x003c7;<sup>2</sup>&#x0200a;=&#x0200a;28.341 and 31.399, respectively; <italic>P</italic>&#x0200a;=&#x0200a;0.000 for both). The highest performed accuracies in P<sub>30</sub> and P<sub>50</sub>, 74.26% and 95.05%, respectively, were observed for eGFR7, followed by eGFR8, with 72.28% and 93.07%, respectively. eGFR2 showed the lowest performed accuracies at 43.56% and 73.27%, respectively, followed by eGFR1 at 55.45% and 77.23%, respectively.</p><p>Overall, eGFR7 showed the highest performed accuracy for rGFR estimation (<xref ref-type="fig" rid="pone-0057240-g002">Figure 2</xref>-B, CR&#x0200a;=&#x0200a;28.5 mL/min &#x02022; 1.73 m<sup>2</sup>).</p><p>As shown in <xref ref-type="table" rid="pone-0057240-t002">Table 2</xref>, the Bland-Altman analysis revealed that the percentage of each eGFR value falling outside the consistency limit was between 3.96 and 6.93%, which were not significantly different (&#x003c7;<sup>2</sup>&#x0200a;=&#x0200a;1.483, <italic>P</italic>&#x0200a;=&#x0200a;0.983). However, the eGFR3, eGFR4 and eGFR8 values were slightly lower than the rGFR values (positive deviation), while others were higher. The consistency limits of six equations were all higher than the previously accepted tolerances (&#x0003c;60 mL/min &#x02022; 1.73 m<sup>2</sup>), while those of eGFR7 and eGFR8 were within the previously accepted tolerances.</p><p>Using the Mountain chart, the newly developed formulas, eGFR7 and eGFR8, and 6 previously reported formulas in the literature were used to estimate the differences in the consistency between the estimated GFR values and the rGFR values (<xref ref-type="fig" rid="pone-0057240-g003">Figure 3</xref>). The median deviation of the distribution curve (M, i.e., P<sub>50</sub>) was used to show their central tendency, with the range of <italic>P</italic>
<sub>5</sub>&#x02013;<italic>P</italic>
<sub>95</sub> (R<italic><sub>P</sub></italic>
<sub>5&#x02013;<italic>P</italic>95</sub>) representing the degree of dispersion (<xref ref-type="table" rid="pone-0057240-t004">Table 4</xref>).</p><fig id="pone-0057240-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057240.g003</object-id><label>Figure 3</label><caption><title>Mountain plot: comparison between newly developed eGFR formulas and various literature eGFR formulas.</title></caption><graphic xlink:href="pone.0057240.g003"/></fig><table-wrap id="pone-0057240-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057240.t004</object-id><label>Table 4</label><caption><title>Percentiles (<italic>P</italic>) of difference between eGFR and rGFR (mL/min &#x02022; 1.73 m<sup>2</sup>).</title></caption><alternatives><graphic id="pone-0057240-t004-4" xlink:href="pone.0057240.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
<sub>5</sub>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
<sub>10</sub>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
<sub>25</sub>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
<sub>50</sub>(<italic>M</italic>)</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
<sub>75</sub>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
<sub>90</sub>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>
<sub>95</sub>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">eGFR1</td><td align="left" rowspan="1" colspan="1">&#x02212;42.52</td><td align="left" rowspan="1" colspan="1">&#x02212;32.93</td><td align="left" rowspan="1" colspan="1">&#x02212;14.24</td><td align="left" rowspan="1" colspan="1">2.85</td><td align="left" rowspan="1" colspan="1">12.12</td><td align="left" rowspan="1" colspan="1">19.06</td><td align="left" rowspan="1" colspan="1">25.91</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR2</td><td align="left" rowspan="1" colspan="1">&#x02212;52.86</td><td align="left" rowspan="1" colspan="1">&#x02212;39.34</td><td align="left" rowspan="1" colspan="1">&#x02212;17.52</td><td align="left" rowspan="1" colspan="1">3.77</td><td align="left" rowspan="1" colspan="1">13.36</td><td align="left" rowspan="1" colspan="1">21.20</td><td align="left" rowspan="1" colspan="1">28.15</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR3</td><td align="left" rowspan="1" colspan="1">&#x02212;22.21</td><td align="left" rowspan="1" colspan="1">&#x02212;15.85</td><td align="left" rowspan="1" colspan="1">&#x02212;2.06</td><td align="left" rowspan="1" colspan="1">6.90</td><td align="left" rowspan="1" colspan="1">14.67</td><td align="left" rowspan="1" colspan="1">23.74</td><td align="left" rowspan="1" colspan="1">29.88</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR4</td><td align="left" rowspan="1" colspan="1">&#x02212;31.91</td><td align="left" rowspan="1" colspan="1">&#x02212;19.84</td><td align="left" rowspan="1" colspan="1">&#x02212;5.28</td><td align="left" rowspan="1" colspan="1">6.63</td><td align="left" rowspan="1" colspan="1">14.80</td><td align="left" rowspan="1" colspan="1">23.82</td><td align="left" rowspan="1" colspan="1">28.48</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR5</td><td align="left" rowspan="1" colspan="1">&#x02212;30.58</td><td align="left" rowspan="1" colspan="1">&#x02212;26.63</td><td align="left" rowspan="1" colspan="1">&#x02212;9.25</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">9.42</td><td align="left" rowspan="1" colspan="1">18.96</td><td align="left" rowspan="1" colspan="1">23.46</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR6</td><td align="left" rowspan="1" colspan="1">&#x02212;45.36</td><td align="left" rowspan="1" colspan="1">&#x02212;29.05</td><td align="left" rowspan="1" colspan="1">&#x02212;11.39</td><td align="left" rowspan="1" colspan="1">2.51</td><td align="left" rowspan="1" colspan="1">11.19</td><td align="left" rowspan="1" colspan="1">19.44</td><td align="left" rowspan="1" colspan="1">23.73</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR7</td><td align="left" rowspan="1" colspan="1">&#x02212;27.94</td><td align="left" rowspan="1" colspan="1">&#x02212;17.96</td><td align="left" rowspan="1" colspan="1">&#x02212;8.31</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">8.89</td><td align="left" rowspan="1" colspan="1">17.13</td><td align="left" rowspan="1" colspan="1">21.00</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR8</td><td align="left" rowspan="1" colspan="1">&#x02212;25.04</td><td align="left" rowspan="1" colspan="1">&#x02212;18.27</td><td align="left" rowspan="1" colspan="1">&#x02212;7.89</td><td align="left" rowspan="1" colspan="1">2.09</td><td align="left" rowspan="1" colspan="1">10.58</td><td align="left" rowspan="1" colspan="1">21.73</td><td align="left" rowspan="1" colspan="1">24.90</td></tr></tbody></table></alternatives></table-wrap><p>Compared with eGFR7 (<italic>M</italic>&#x0200a;=&#x0200a;0.01, R<italic><sub>P</sub></italic>
<sub>5&#x02013;<italic>P</italic>95</sub>&#x0200a;=&#x0200a;48.94 mL/min &#x02022; 1.73 m<sup>2</sup>), eGFR1-6 all showed a larger M of deviation with rGFR (the <italic>M</italic> were 2.85, 3.77, 6.90, 6.63, 0.88 and 2.51 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively) and wider curve distribution (the R<italic><sub>P</sub></italic>
<sub>5-<italic>P</italic>95</sub> were 68.43, 81.01, 52.09, 60.39, 54.04 and 69.09 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively), indicating that their GFR estimation was worse than eGFR7 (<xref ref-type="fig" rid="pone-0057240-g003">Figure 3</xref>-A, B, and C-F). Among eGFR1-6, eGFR3 and eGFR4 showed an apparent rightward shift in their error distribution curves (<italic>P</italic>
<sub>5</sub>, <italic>M</italic> and <italic>P</italic>
<sub>95</sub> were all larger than eGFR7) (<xref ref-type="fig" rid="pone-0057240-g003">Figure 3</xref>-C and D), indicating overall underestimation of GFR by these two.</p><p>Similar results to those reported with eGFR7 were obtained with eGFR8 and all 6 previously reported equations (therefore, not shown, charted repeatedly). As shown in <xref ref-type="fig" rid="pone-0057240-g003">Figure 3</xref>-G, the deviation curves of eGFR7 and eGFR8 almost overlapped, indicating basically the same consistency in estimating the GFR.</p><p>
<xref ref-type="table" rid="pone-0057240-t005">Table 5</xref> shows how many patients(percentage) were correctly classified for the different stages of CKD, according to GFR estimating equations based upon SCr and/or CysC. Overall a correct classification was achieved in 43.6% to 65.3% of the patients with the traditional eGFR equations and 73.3% to 74.3% with the new eGFR equations. The best percentage (74.3%) was achieved with the eGFR8, however, the eGFR7 gave a very close result 73.3%.</p><table-wrap id="pone-0057240-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057240.t005</object-id><label>Table 5</label><caption><title>Classification of CKD by SCr- and/or CysC-based on eGFR equations(n&#x0200a;=&#x0200a;101)<xref ref-type="table-fn" rid="nt104">*</xref>.</title></caption><alternatives><graphic id="pone-0057240-t005-5" xlink:href="pone.0057240.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CKD1</td><td align="left" rowspan="1" colspan="1">CKD2</td><td align="left" rowspan="1" colspan="1">CKD3</td><td align="left" rowspan="1" colspan="1">CKD4</td><td align="left" rowspan="1" colspan="1">CKD5</td><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">&#x003ba;(95%CI)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rGFR</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">eGFR1</td><td align="left" rowspan="1" colspan="1">7(53.8)<sup>&#x02605;</sup>
</td><td align="left" rowspan="1" colspan="1">14(63.6)</td><td align="left" rowspan="1" colspan="1">28(63.6)</td><td align="left" rowspan="1" colspan="1">5(29.4)</td><td align="left" rowspan="1" colspan="1">2(40.0)</td><td align="left" rowspan="1" colspan="1">56(55.4)</td><td align="left" rowspan="1" colspan="1">0.403(0.280&#x02013;0.526)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR2</td><td align="left" rowspan="1" colspan="1">7(53.8)</td><td align="left" rowspan="1" colspan="1">15(68.2)</td><td align="left" rowspan="1" colspan="1">19(43.2)</td><td align="left" rowspan="1" colspan="1">3(17.6)</td><td align="left" rowspan="1" colspan="1">2(40.0)</td><td align="left" rowspan="1" colspan="1">44(43.6)</td><td align="left" rowspan="1" colspan="1">0.297(0.175&#x02013;0.419)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR3</td><td align="left" rowspan="1" colspan="1">10(76.9)</td><td align="left" rowspan="1" colspan="1">17(77.3)</td><td align="left" rowspan="1" colspan="1">26(59.1)</td><td align="left" rowspan="1" colspan="1">7(41.2)</td><td align="left" rowspan="1" colspan="1">3(60.0)</td><td align="left" rowspan="1" colspan="1">63(62.4)</td><td align="left" rowspan="1" colspan="1">0.504(0.382&#x02013;0.626)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR4</td><td align="left" rowspan="1" colspan="1">11(84.6)</td><td align="left" rowspan="1" colspan="1">17(77.3)</td><td align="left" rowspan="1" colspan="1">29(65.9)</td><td align="left" rowspan="1" colspan="1">5(29.4)</td><td align="left" rowspan="1" colspan="1">2(40.0)</td><td align="left" rowspan="1" colspan="1">64(63.4)</td><td align="left" rowspan="1" colspan="1">0.514(0.394&#x02013;0.634)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR5</td><td align="left" rowspan="1" colspan="1">12(92.3)</td><td align="left" rowspan="1" colspan="1">14(63.6)</td><td align="left" rowspan="1" colspan="1">28(63.6)</td><td align="left" rowspan="1" colspan="1">9(52.9)</td><td align="left" rowspan="1" colspan="1">3(60.0)</td><td align="left" rowspan="1" colspan="1">66(65.3)</td><td align="left" rowspan="1" colspan="1">0.536(0.413&#x02013;0.659)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR6</td><td align="left" rowspan="1" colspan="1">11(84.6)</td><td align="left" rowspan="1" colspan="1">14(63.6)</td><td align="left" rowspan="1" colspan="1">27(61.4)</td><td align="left" rowspan="1" colspan="1">7(41.2)</td><td align="left" rowspan="1" colspan="1">2(40.0)</td><td align="left" rowspan="1" colspan="1">61(60.4)</td><td align="left" rowspan="1" colspan="1">0.472(0.347&#x02013;0.597)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR7</td><td align="left" rowspan="1" colspan="1">12(92.3)</td><td align="left" rowspan="1" colspan="1">18(81.8)</td><td align="left" rowspan="1" colspan="1">32(72.7)</td><td align="left" rowspan="1" colspan="1">9(52.9)</td><td align="left" rowspan="1" colspan="1">3(60.0)</td><td align="left" rowspan="1" colspan="1">74(73.3)</td><td align="left" rowspan="1" colspan="1">0.641(0.527&#x02013;0.755)</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR8</td><td align="left" rowspan="1" colspan="1">12(92.3)</td><td align="left" rowspan="1" colspan="1">18(81.8)</td><td align="left" rowspan="1" colspan="1">33(75.0)</td><td align="left" rowspan="1" colspan="1">10(58.8)</td><td align="left" rowspan="1" colspan="1">2(40.0)</td><td align="left" rowspan="1" colspan="1">75(74.3)</td><td align="left" rowspan="1" colspan="1">0.652(0.538&#x02013;0.766)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt104"><label>*</label><p>Accoding to the recommendations by K/DOQI. <sup>&#x02605;</sup>Number of patients (%) correct classified. Reference method is plasma clearance of <sup>99m</sup>Tc-DTPA. Kappa analysis was used to evaluate the agreement between rGFR stages and each eGFR CKD stages.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>GFR is traditionally considered to be the best overall index of the kidney function. Therefore, its accurate detection is critical for early diagnosis, proper staging, effective treatment and monitoring of CKD. The International Association of Nuclear Medicine has recommended the two-serum method to measure the clearance rate of <sup>99m</sup>Tc-DTPA as the reference method for GFR detection <xref rid="pone.0057240-Blaufox1" ref-type="bibr">[35]</xref>. However, this method is difficult for clinical applications because of its complexity, high costs, high equipment requirement and radioactivity.</p><p>The PETIA-CysC is comparable with PENIA-CysC in accuracy, but PETIA-CysC can be detected using various types of automatic biochemical analyzers, so its detection speed is faster than PENIA-CysC and it can be easily and broadly applied in clinical laboratories. Therefore, many clinical laboratories have detected CysC using the PETIA-CysC method <xref rid="pone.0057240-Sohrabian2" ref-type="bibr">[36]</xref>&#x02013;<xref rid="pone.0057240-Bargnoux3" ref-type="bibr">[40]</xref>. In addition, enzymatic detection of serum Cr shows less interference and low cross-contamination between samples <xref rid="pone.0057240-Greenberg1" ref-type="bibr">[26]</xref>&#x02013;<xref rid="pone.0057240-Wang1" ref-type="bibr">[28]</xref>; therefore, it is also widely used by clinical laboratories.</p><p>In this study, we used the two-serum method <sup>99m</sup>Tc-DTPA clearance rate as the &#x0201c;gold standard&#x0201d; and determined serum Cr with the enzyme-based method. We determined the serial CysC of 687 randomly selected Chinese CKD patients using the PETIA method. Two GFR estimating equations were established based on the top coefficient of the non-linear regression iterative calculation:<disp-formula id="pone.0057240.e012"><graphic xlink:href="pone.0057240.e012.jpg" position="anchor" orientation="portrait"/></disp-formula>
<disp-formula id="pone.0057240.e013"><graphic xlink:href="pone.0057240.e013.jpg" position="anchor" orientation="portrait"/></disp-formula>
</p><p>The R<sup>2</sup> of eGFR8 was higher than that of eGFR7, indicating that using both Cr and age for GFR estimation was not as effective as using CysC alone. Therefore, CysC has the potential to be a good substitute for Cr during the assessment of renal function.</p><p>The two equations developed in this study had limits of agreement (57.0 mL/min &#x02022; 1.73 m<sup>2</sup> and 59.5 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively) that were within the pre-set values of &#x0003c;60 mL/min &#x02022; 1.73 m<sup>2</sup>. They also showed only minor differences in their Mountain deviation distribution curves, with almost the same error (367 vs. 377 arbitrary units), precision (28.5 vs. 29.7 mL/min &#x02022; 1.73 m<sup>2</sup>), accuracy (<italic>P</italic>&#x0003e;0.05), and applicability in GFR estimation. When comparing the newly developed equations and the 6 previously reported ones, only eGFR7 and eGFR8 did not show apparent proportional errors (b's 95% CI contains B&#x0200a;=&#x0200a;1) and constant errors (a's 95% CI contains A&#x0200a;=&#x0200a;0) from rGFR. All equations showed high linear correlations (r&#x0003e;0.75, <italic>P</italic>&#x0200a;=&#x0200a;0.000) and acceptable Passing &#x00026; Bablok regression linearity (Cusum test, <italic>P</italic>&#x0003e;0.05). Among these 6 previous equations, eGFR3 had only constant errors (a's 95% CI&#x0200a;=&#x0200a;&#x02212;12.592 and &#x02212;2.989, not containing 0) from rGFR, but all the other equations had both constant errors and proportional errors. These errors may have been caused by the differences in study subjects, GFR &#x0201c;gold standards&#x0201d;, GFR markers, and GFR determination methods, which may be verified by the following comparisons of the newly developed equations and the literature equations.</p><p>In the estimation of GFR consistency, eGFR7 and eGFR8 were both better than eGFR1 and eGFR2 (limits of agreement&#x0200a;=&#x0200a;57.0 and 59.5 vs. 98.7 and 111.5 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively), and the limits of consistency for the latter two were both significantly higher than the pre-set professional cutoff value (&#x0003c;60 mL/min &#x02022; 1.73 m<sup>2</sup>). eGFR7 and eGFR8 also had smaller GFR estimating errors than eGFR1 and eGFR2 (367 and 377 vs. 2045 and 3036 arbitrary units, respectively). eGFR1 and eGFR2 also had worse estimation accuracy (CR&#x0200a;=&#x0200a;49.3 and 55.8 <italic>vs.</italic> 28.5 and 29.7 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively) and lower P<sub>30</sub> and P<sub>50</sub> than eGFR7 and eGFR8 (<italic>&#x003c7;</italic>
<sup>2</sup> test, <italic>P</italic>&#x0003c;0.05). The serum Cr can be easily affected by many factors, such as gender, age, muscle size, diet, medication and renal secretion and excretion (renal excretion becomes more apparent under pathological conditions), which may lead to the large errors and low accuracy of eGFR1 and eGFR2 in GFR estimation. In addition, the choice of Cr determination may also affect the applicability of eGFR1 and eGFR2. It was reported that eGFR1 was better than eGFR2 when the enzyme-based measurement was selected <xref rid="pone.0057240-Liu3" ref-type="bibr">[41]</xref>. A similar conclusion was reached in this study.</p><p>The two equations for MDRD/CKD-EPI, eGFR3 and eGFR4, with the limits of agreement being higher than the pre-set values of &#x0003c;60 mL/min &#x02022; 1.73 m<sup>2</sup> at 61.8 and 72.3 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively, were also worse than eGFR7 and eGFR8 in the GFR estimation for Chinese CKD patients. The Mountain deviation distribution curves of eGFR3 and eGFR4 both deviated to the right from the &#x0201c;0&#x0201d; point (M&#x0200a;=&#x0200a;6.90 and 6.63 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively,) with larger <italic>P</italic>
<sub>5</sub>, <italic>M</italic> and <italic>P</italic>
<sub>95</sub> than those of eGFR7 and eGFR8, indicating significant underestimation of GFR for Chinese CKD patients. Therefore, the MDRD/CKD-EPI equations may only have limited application in Chinese populations.</p><p>The two equations from the Chinese cooperative group, eGFR5 and eGFR6, did target the Chinese populations. However, their limits of agreement (65.6 and 80.8 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively,)) both exceeded the pre-set values of &#x0003c;60 mL/min &#x02022; 1.73 m<sup>2</sup>. Compared with eGFR7 and eGFR8, eGFR5 and eGFR6 showed broadening trends in the Mountain deviation distributions (<italic>P</italic>
<sub>5</sub>&#x02013;<italic>P</italic>
<sub>95</sub> interval distribution width&#x0200a;=&#x0200a;54.04 and 69.09 vs. 48.94 and 49.94 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively,)), worse precision (CR&#x0200a;=&#x0200a;32.8 and 40.4 vs. 28.5 and 29.7 mL/min &#x02022; 1.73 m<sup>2</sup>, respectively,)), and worse accuracy (P<sub>30</sub>: eGFR6 <italic>vs.</italic> eGFR7, <italic>&#x003c7;</italic>
<sup>2</sup> test, <italic>P</italic>&#x0003c;0.05; P<sub>50</sub>: eGFR6 <italic>vs.</italic> eGFR7 and eGFR8, <italic>&#x003c7;</italic>
<sup>2</sup> test, <italic>P</italic>&#x0003c;0.05), all of which indicate inferior consistency for rGFR.</p><p>In addition to the factor of race, differences in the determination methods for GFR markers, i.e., the different methods of detecting Cr and CysC, may also contribute to the deviation of the results between the newly developed equations and the previously reported ones. In the past, the picric acid assay was used to detect serum Cr (eGFR1-eGFR6 equations). Currently, many laboratories in China prefer the enzyme-based method to detect serum Cr in order to avoid cross contamination from picric acid. Routine CysC tests also include the PETIA and PENIA methods. Because it can be performed in an automatic biochemical analyzer and the detection time can be as short as 5 minutes, PETIA has become the preferred method for CysC routine determinations. The MDRD/CKD-EPI and the Chinese collaboration group, however, used PENIA instead of PETIA to detect serum CysC (eGFR3-eGFR6 equations). In addition, the differences in CysC standards may also cause differences in detection results, which affect the applicability of eGFR equations. The first CysC certified reference material ERM-DA471/IFCC <xref rid="pone.0057240-Grubb1" ref-type="bibr">[42]</xref> was introduced in 2010, which allows CysC detection to be traced. As a result, studies on CysC-based GFR estimation equations may avoid matrix effects. Once serum CysC detection becomes standardized, its application in GFR evaluation will have greater advantages over Cr detection. In this study, we developed two eGFR equations based on the sole-indicator, CysC, in combination with serum creatinine levels and age, to evaluate renal functions precisely, accurately, simply and quickly with lower costs.</p><p>The difference of results between our new equation and traditional eGFR equations, largely may be due to different measured methods for the determination of SCr and CysC. That is, entered enzymatic-Cr results and/or PETIA-CysC results to traditional eGFR equations that were developed by Cr using the Jaffe's kinetic method and/or PENIA-CysC. It is this inadequate use that leads to the eGFR calculation resulting error. Of course, different choices of the "gold standard" in research programs, as well as technical proficiency of the same "gold standard" may also be the reasons of the error. In addition, the population differences in development group, such as the difference of the constituent ratio of the subjects age, sex, CKD stage, and complications, etc., may also be the reason that the results are not consistent between the traditional eGFR equations and this study equation. In this study, there are statistical differences between gender for weight, height, and body surface area. It will worth considering whether they will cause the differences of the traditional eGFR results.</p><p>It is worth mentioning that although the meta-analysis demonstrated that CysC is superior to SCr in the determination of the GFR injuries <xref rid="pone.0057240-Dharnidharka1" ref-type="bibr">[43]</xref>, <xref rid="pone.0057240-Roos2" ref-type="bibr">[44]</xref>. However, most studies of CysC have focused on fields where the problems of SCr are most apparent, including specific population groups with malnutrition, extensive reduced body surface area, extremely low body mass, or a few comorbidities that have a large influence on the generation of creatinine. Nevertheless, Serum cystatin C may be influenced by factors other than renal function alone, including serum C-reactive protein <xref rid="pone.0057240-Stevens2" ref-type="bibr">[45]</xref>, smoking <xref rid="pone.0057240-Sjostrom1" ref-type="bibr">[46]</xref>, the subjects with very low GFR<xref rid="pone.0057240-Horio1" ref-type="bibr">[47]</xref>, thyroid function <xref rid="pone.0057240-Kotajima1" ref-type="bibr">[48]</xref>, <xref rid="pone.0057240-Fricker1" ref-type="bibr">[49]</xref>, immunosuppressive therapy <xref rid="pone.0057240-Rule1" ref-type="bibr">[50]</xref>, and occupational exposure to toxic agents such as lead, cadmium, and arsenic <xref rid="pone.0057240-Porba1" ref-type="bibr">[51]</xref>, etc. Thus, clinicians must be cautious when interpreting cystatin C levels alone if the subjects encounter these factors.In summary, different fitting eGFR equations with different estimation values can be developed based on different study subjects, different GFR &#x0201c;gold standards&#x0201d;, and different detection methods. The two newly established equations in this study showed effective but significantly different results from previously reported equations, most likely a result of the differences in detection methods and &#x0201c;gold standards&#x0201d;. Currently, enzyme-based Cr detection and CysC PETIA detection are widely used in clinical laboratories. Our study demonstrated that the simple cystatin C formula could achieve a much better diagnostic performance than SCr formula containing more variables.Therefore, careful and complete consideration is required to choose the right eGFR equation for clinical applications to avoid misdiagnosis and errors in treatment.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0057240.s001"><label>Appendix S1</label><caption><p>Representative patient's signed permit for Glomerular Filtration Rate(GFR) Measurement Using Radiochemical 99mTc-DTPA in Chinese Version.</p><p>(PDF)</p></caption><media xlink:href="pone.0057240.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0057240.s002"><label>Appendix S2</label><caption><p>Representative patient's signed permit for publication in PLoS ONE in English Version.</p><p>(PDF)</p></caption><media xlink:href="pone.0057240.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0057240-Levey1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Levey</surname><given-names>AS</given-names></name>, <name><surname>Atkins</surname><given-names>R</given-names></name>, <name><surname>Coresh</surname><given-names>J</given-names></name>, <name><surname>Cohen</surname><given-names>EP</given-names></name>, <name><surname>Collins</surname><given-names>AJ</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Chronic kidney disease as a global public health problem: approaches and initiatives- a position statement from Kidney Disease Improving Global Outcomes</article-title>. <source>Kidney Int</source>
<volume>72</volume>: <fpage>247</fpage>&#x02013;<lpage>259</lpage>.<pub-id pub-id-type="pmid">17568785</pub-id></mixed-citation></ref><ref id="pone.0057240-Levey2"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Levey</surname><given-names>AS</given-names></name>, <name><surname>Eckardt</surname><given-names>KU</given-names></name>, <name><surname>Tsukamoto</surname><given-names>Y</given-names></name>, <name><surname>Levin</surname><given-names>A</given-names></name>, <name><surname>Coresh</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)</article-title>. <source>Kidney Int</source>
<volume>67</volume>: <fpage>2089</fpage>&#x02013;<lpage>2100</lpage>.<pub-id pub-id-type="pmid">15882252</pub-id></mixed-citation></ref><ref id="pone.0057240-National1"><label>3</label><mixed-citation publication-type="journal">
<collab>National Kidney Foundation</collab> (<year>2002</year>) <article-title>NFK-K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification</article-title>. <source>Am J Kidney Dis</source>
<volume>39</volume>: <fpage>S1</fpage>&#x02013;<lpage>S266</lpage>.<pub-id pub-id-type="pmid">11904577</pub-id></mixed-citation></ref><ref id="pone.0057240-Florkowski1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Florkowski</surname><given-names>CM</given-names></name>, <name><surname>Chew-Harris</surname><given-names>JS</given-names></name> (<year>2011</year>) <article-title>Methods of Estimating GFR-Different Equations Including CKD-EPI</article-title>. <source>Clin Biochem Rev</source>
<volume>32</volume>: <fpage>75</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21611080</pub-id></mixed-citation></ref><ref id="pone.0057240-Hojs1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Hojs</surname><given-names>R</given-names></name>, <name><surname>Bevc</surname><given-names>S</given-names></name>, <name><surname>Ekart</surname><given-names>R</given-names></name>, <name><surname>Gorenjak</surname><given-names>M</given-names></name>, <name><surname>Puklavec</surname><given-names>L</given-names></name> (<year>2008</year>) <article-title>Serum cystatin C as an endogenous marker of renal function in patients with chronic kidney disease</article-title>. <source>Ren Fail</source>
<volume>30</volume>: <fpage>181</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">18300118</pub-id></mixed-citation></ref><ref id="pone.0057240-Inker1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Inker</surname><given-names>LA</given-names></name>, <name><surname>Schmid</surname><given-names>CH</given-names></name>, <name><surname>Tighiouart</surname><given-names>H</given-names></name>, <name><surname>Eckfeldt</surname><given-names>JH</given-names></name>, <name><surname>Feldman</surname><given-names>HI</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>CKD-EPI Investigators</article-title>. <source>Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med</source>
<volume>367</volume>: <fpage>20</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22762315</pub-id></mixed-citation></ref><ref id="pone.0057240-Slort1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Slort</surname><given-names>PR</given-names></name>, <name><surname>Ozden</surname><given-names>N</given-names></name>, <name><surname>Pape</surname><given-names>L</given-names></name>, <name><surname>Offner</surname><given-names>G</given-names></name>, <name><surname>Tromp</surname><given-names>WF</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Comparing cystatin C and creatinine in the diagnosis of pediatric acute renal allograft dysfunction</article-title>. <source>Pediatr Nephrol</source>
<volume>27</volume>: <fpage>843</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22207347</pub-id></mixed-citation></ref><ref id="pone.0057240-Larsson1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Larsson</surname><given-names>A</given-names></name>, <name><surname>Flodin</surname><given-names>M</given-names></name>, <name><surname>Hansson</surname><given-names>LO</given-names></name>, <name><surname>Carlsson</surname><given-names>L</given-names></name> (<year>2008</year>) <article-title>Patient selection has a strong impact on cystatin C and Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration rate</article-title>. <source>Clin Biochem</source>
<volume>41</volume>: <fpage>1355</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">18674527</pub-id></mixed-citation></ref><ref id="pone.0057240-Salgado1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Salgado</surname><given-names>JV</given-names></name>, <name><surname>Neves</surname><given-names>FA</given-names></name>, <name><surname>Bastos</surname><given-names>MG</given-names></name>, <name><surname>Fran&#x000e7;a</surname><given-names>AK</given-names></name>, <name><surname>Brito</surname><given-names>DJ</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Monitoring renal function: measured and estimated glomerular filtration rates- a review</article-title>. <source>Braz J Med Biol Res</source>
<volume>43</volume>: <fpage>528</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">20464341</pub-id></mixed-citation></ref><ref id="pone.0057240-Roos1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Roos</surname><given-names>JF</given-names></name>, <name><surname>Doust</surname><given-names>J</given-names></name>, <name><surname>Tett</surname><given-names>SE</given-names></name>, <name><surname>Kirkpatrick</surname><given-names>CM</given-names></name> (<year>2007</year>) <article-title>Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children- a meta-analysis</article-title>. <source>Clin Biochem</source>
<volume>40</volume>: <fpage>383</fpage>&#x02013;<lpage>391</lpage>.<pub-id pub-id-type="pmid">17316593</pub-id></mixed-citation></ref><ref id="pone.0057240-Ferguson1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Ferguson</surname><given-names>MA</given-names></name>, <name><surname>Waikar</surname><given-names>SS</given-names></name> (<year>2012</year>) <article-title>Established and emerging markers of kidney function</article-title>. <source>Clin Chem</source>
<volume>58</volume>: <fpage>680</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22311920</pub-id></mixed-citation></ref><ref id="pone.0057240-HergetRosenthal1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Herget-Rosenthal</surname><given-names>S</given-names></name>, <name><surname>Feldkamp</surname><given-names>T</given-names></name>, <name><surname>Volbracht</surname><given-names>L</given-names></name>, <name><surname>Kribben</surname><given-names>A</given-names></name> (<year>2004</year>) <article-title>Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range</article-title>. <source>Ann Clin Biochem</source>
<volume>41</volume> (<issue>(Pt 2)</issue>) <fpage>111</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15025800</pub-id></mixed-citation></ref><ref id="pone.0057240-Voskoboev1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Voskoboev</surname><given-names>NV</given-names></name>, <name><surname>Larson</surname><given-names>TS</given-names></name>, <name><surname>Rule</surname><given-names>AD</given-names></name>, <name><surname>Lieske</surname><given-names>JC</given-names></name> (<year>2012</year>) <article-title>Analytic and clinical validation of a standardized cystatin C particle enhanced turbidimetric assay (PETIA) to estimate glomerular filtration rate</article-title>. <source>Clin Chem Lab Med</source>
<volume>50</volume>: <fpage>1591</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22962219</pub-id></mixed-citation></ref><ref id="pone.0057240-Liu1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>J</given-names></name> (<year>2012</year>) <article-title>Evaluation of serum cystatin C for diagnosis of acute rejection after renal transplantation</article-title>. <source>Transplant Proc</source>
<volume>44</volume>: <fpage>1250</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">22663994</pub-id></mixed-citation></ref><ref id="pone.0057240-Cai1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Cai</surname><given-names>X</given-names></name>, <name><surname>Long</surname><given-names>Z</given-names></name>, <name><surname>Lin</surname><given-names>L</given-names></name>, <name><surname>Feng</surname><given-names>Y</given-names></name>, <name><surname>Zhou</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Serum cystatin C is an early biomarker for assessment of renal function in burn patients</article-title>. <source>Clin Chem Lab Med</source>
<volume>50</volume>: <fpage>667</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">22505558</pub-id></mixed-citation></ref><ref id="pone.0057240-Krishnamurthy1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Krishnamurthy</surname><given-names>N</given-names></name>, <name><surname>Arumugasamy</surname><given-names>K</given-names></name>, <name><surname>Anand</surname><given-names>U</given-names></name>, <name><surname>Anand</surname><given-names>CV</given-names></name>, <name><surname>Aruna</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Serum cystatin C levels in renal transplant recipients</article-title>. <source>Indian J Clin Biochem</source>
<volume>26</volume>: <fpage>120</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">22468036</pub-id></mixed-citation></ref><ref id="pone.0057240-Kumaresan1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Kumaresan</surname><given-names>R</given-names></name>, <name><surname>Giri</surname><given-names>P</given-names></name> (<year>2011</year>) <article-title>A comparison of serum cystatin C and creatinine with glomerular filtration rate in Indian patients with chronic kidney disease</article-title>. <source>Oman Med J</source>
<volume>26</volume>: <fpage>421</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22253951</pub-id></mixed-citation></ref><ref id="pone.0057240-Yap1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Yap</surname><given-names>M</given-names></name>, <name><surname>Lamarche</surname><given-names>J</given-names></name>, <name><surname>Peguero</surname><given-names>A</given-names></name>, <name><surname>Courville</surname><given-names>C</given-names></name> (<year>2011</year>) <article-title>Serum cystatin C versus serum creatinine in the estimation of glomerular filtration rate in rhabdomyolysis.J Ren Care</article-title>. <volume>37</volume>: <fpage>155</fpage>&#x02013;<lpage>7.19</lpage>.</mixed-citation></ref><ref id="pone.0057240-Jaisuresh1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Jaisuresh</surname><given-names>K</given-names></name>, <name><surname>Sharma</surname><given-names>RK</given-names></name>, <name><surname>Mehrothra</surname><given-names>S</given-names></name>, <name><surname>Kaul</surname><given-names>A</given-names></name>, <name><surname>Badauria</surname><given-names>DS</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Cystatin C as a marker of glomerular filtration rate in voluntary kidney donors</article-title>. <source>Exp Clin Transplant</source>
<volume>10</volume>: <fpage>14</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22309414</pub-id></mixed-citation></ref><ref id="pone.0057240-Robles1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Robles</surname><given-names>NR</given-names></name>, <name><surname>Mena</surname><given-names>C</given-names></name>, <name><surname>Cidoncha</surname><given-names>J</given-names></name> (<year>2012</year>) <article-title>Estimated Glomerular Filtration Rate from Serum Cystatin C: Significant Differences among Several Equations Results</article-title>. <source>Ren Fail</source>
<volume>34</volume>: <fpage>871</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22680249</pub-id></mixed-citation></ref><ref id="pone.0057240-Hojs2"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Hojs</surname><given-names>R</given-names></name>, <name><surname>Bevc</surname><given-names>S</given-names></name>, <name><surname>Ekart</surname><given-names>R</given-names></name>, <name><surname>Gorenjak</surname><given-names>M</given-names></name>, <name><surname>Puklavec</surname><given-names>L</given-names></name> (<year>2010</year>) <article-title>Serum cystatin C-based formulas for prediction of glomerular filtration rate in patients with chronic kidney disease</article-title>. <source>Nephron Clin Pract</source>
<volume>114</volume>: <fpage>c118</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">19887832</pub-id></mixed-citation></ref><ref id="pone.0057240-Sohrabian1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Sohrabian</surname><given-names>A</given-names></name>, <name><surname>Noraddin</surname><given-names>FH</given-names></name>, <name><surname>Flodin</surname><given-names>M</given-names></name>, <name><surname>Fredricsson</surname><given-names>A</given-names></name>, <name><surname>Larsson</surname><given-names>A</given-names></name> (<year>2012</year>) <article-title>Particle enhanced turbidimetric immunoassay for the determination of urine cystatin C on Cobas c501</article-title>. <source>Clin Biochem</source>
<volume>45</volume>: <fpage>339</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22266397</pub-id></mixed-citation></ref><ref id="pone.0057240-Bargnoux1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Bargnoux</surname><given-names>AS</given-names></name>, <name><surname>Cavalier</surname><given-names>E</given-names></name>, <name><surname>Cristol</surname><given-names>JP</given-names></name>, <name><surname>Simon</surname><given-names>N</given-names></name>, <name><surname>Dupuy</surname><given-names>AM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Cystatin C is a reliable marker for estimation of glomerular filtration rate in renal transplantation: validation of a new turbidimetric assay using monospecific sheep antibodies</article-title>. <source>Clin Chem Lab Med</source>
<volume>49</volume>: <fpage>265</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">21110777</pub-id></mixed-citation></ref><ref id="pone.0057240-Bargnoux2"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Bargnoux</surname><given-names>AS</given-names></name>, <name><surname>Perrin</surname><given-names>M</given-names></name>, <name><surname>Garrigue</surname><given-names>V</given-names></name>, <name><surname>Badiou</surname><given-names>S</given-names></name>, <name><surname>Dupuy</surname><given-names>AM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Analytical performances of cystatin C turbidimetric assay: which impact on accuracy of glomerular filtration rate estimation in renal transplantation?</article-title>
<source>Clin Chem Lab Med</source>
<volume>50</volume>: <fpage>133</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21942853</pub-id></mixed-citation></ref><ref id="pone.0057240-Hansson1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Hansson</surname><given-names>LO</given-names></name>, <name><surname>Grubb</surname><given-names>A</given-names></name>, <name><surname>Lid&#x000e9;n</surname><given-names>A</given-names></name>, <name><surname>Flodin</surname><given-names>M</given-names></name>, <name><surname>Berggren</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Performance evaluation of a turbidimetric cystatin C assay on different high-throughput platforms</article-title>. <source>Scand J Clin Lab Invest</source>
<volume>70</volume>: <fpage>347</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">20545461</pub-id></mixed-citation></ref><ref id="pone.0057240-Greenberg1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Greenberg</surname><given-names>N</given-names></name>, <name><surname>Roberts</surname><given-names>WL</given-names></name>, <name><surname>Bachmann</surname><given-names>LM</given-names></name>, <name><surname>Wright</surname><given-names>EC</given-names></name>, <name><surname>Dalton</surname><given-names>RN</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Clin Specificity characteristics of 7 commercial creatinine measurement procedures by enzymatic and Jaffe method principles</article-title>. <source>Chem</source>
<volume>58</volume>: <fpage>391</fpage>&#x02013;<lpage>401</lpage>.</mixed-citation></ref><ref id="pone.0057240-Liu2"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>WS</given-names></name>, <name><surname>Chung</surname><given-names>YT</given-names></name>, <name><surname>Yang</surname><given-names>CY</given-names></name>, <name><surname>Lin</surname><given-names>CC</given-names></name>, <name><surname>Tsai</surname><given-names>KH</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Serum creatinine determined by Jaffe, enzymatic method, and isotope dilution-liquid chromatography-mass spectrometry in patients under hemodialysis</article-title>. <source>J Clin Lab Anal</source>
<volume>26</volume>: <fpage>206</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">22628238</pub-id></mixed-citation></ref><ref id="pone.0057240-Wang1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Xu</surname><given-names>G</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>F</given-names></name> (<year>2011</year>) <article-title>Reference intervals for serum creatinine with enzymatic assay and evaluation of four equations to estimate glomerular filtration rate in a healthy Chinese adult population</article-title>. <source>Clin Chim Acta</source>
<volume>412</volume>: <fpage>1793</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21672534</pub-id></mixed-citation></ref><ref id="pone.0057240-Ma1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Ma</surname><given-names>YC</given-names></name>, <name><surname>Zuo</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>CL</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Wang</surname><given-names>RF</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Comparison of <sup>99m</sup>Tc-DTPA renal dynamic imaging with modified MDRD equation for glomerular filtration rate estimation in Chinese patients in different stages of chronic kidney disease</article-title>. <source>Nephrol Dial Transplant</source>
<volume>22</volume>: <fpage>417</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">17053082</pub-id></mixed-citation></ref><ref id="pone.0057240-Cockcroft1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Cockcroft</surname><given-names>DW</given-names></name>, <name><surname>Gault</surname><given-names>MH</given-names></name> (<year>1976</year>) <article-title>Prediction of creatinine clearance from serum creatinine</article-title>. <source>Nephron</source>
<volume>16</volume>: <fpage>31</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">1244564</pub-id></mixed-citation></ref><ref id="pone.0057240-Ma2"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Ma</surname><given-names>YC</given-names></name>, <name><surname>Zuo</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>JH</given-names></name>, <name><surname>Luo</surname><given-names>Q</given-names></name>, <name><surname>Yu</surname><given-names>XQ</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease</article-title>. <source>J Am Soc Nephrol</source>
<volume>17</volume>: <fpage>2937</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">16988059</pub-id></mixed-citation></ref><ref id="pone.0057240-Stevens1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Stevens</surname><given-names>LA</given-names></name>, <name><surname>Coresh</surname><given-names>J</given-names></name>, <name><surname>Schmid</surname><given-names>CH</given-names></name>, <name><surname>Feldman</surname><given-names>HI</given-names></name>, <name><surname>Froissart</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Estimating GFR using Serum Cystatin C Alone and in Combination with Serum Creatinine: A Pooled Analysis of 3418 Individuals with CKD[J]</article-title>. <source>Am J Kidney Dis</source>
<volume>51</volume>: <fpage>395</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">18295055</pub-id></mixed-citation></ref><ref id="pone.0057240-Ma3"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Ma</surname><given-names>YC</given-names></name>, <name><surname>Zuo</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>JH</given-names></name>, <name><surname>Luo</surname><given-names>Q</given-names></name>, <name><surname>Yu</surname><given-names>XQ</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Improved GFR estimation by combined creatinine and cystatin C measurements</article-title>. <source>Kidney Int</source>
<volume>72</volume>: <fpage>1535</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">17898698</pub-id></mixed-citation></ref><ref id="pone.0057240-Bland1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Bland</surname><given-names>JM</given-names></name>, <name><surname>Altman</surname><given-names>DG</given-names></name> (<year>1986</year>) <article-title>Statistical methods for assessing agreement between two methods of clinical measurement</article-title>. <source>Lancet</source>
<volume>1</volume>: <fpage>307</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">2868172</pub-id></mixed-citation></ref><ref id="pone.0057240-Blaufox1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Blaufox</surname><given-names>MD</given-names></name>, <name><surname>Aurell</surname><given-names>M</given-names></name>, <name><surname>Bubeck</surname><given-names>B</given-names></name>, <name><surname>Fommei</surname><given-names>E</given-names></name>, <name><surname>Piepsz</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Report of the Radionuclides in Nephrourology Committee on renal clearance</article-title>. <source>J Nucl Med</source>
<volume>37</volume>: <fpage>1883</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">8917197</pub-id></mixed-citation></ref><ref id="pone.0057240-Sohrabian2"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Sohrabian</surname><given-names>A</given-names></name>, <name><surname>Noraddin</surname><given-names>FH</given-names></name>, <name><surname>Flodin</surname><given-names>M</given-names></name>, <name><surname>Fredricsson</surname><given-names>A</given-names></name>, <name><surname>Larsson</surname><given-names>A</given-names></name> (<year>2012</year>) <article-title>Particle enhanced turbidimetric immunoassay for the determination of urine cystatin C on Cobas c501</article-title>. <source>Clin Biochem</source>
<volume>45</volume>: <fpage>339</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22266397</pub-id></mixed-citation></ref><ref id="pone.0057240-AlTurkmani1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Al-Turkmani</surname><given-names>MR</given-names></name>, <name><surname>Law</surname><given-names>T</given-names></name>, <name><surname>Kellogg</surname><given-names>MD</given-names></name> (<year>2008</year>) <article-title>Performance evaluation of a particle-enhanced turbidimetric cystatin C assay on the Hitachi 917 analyzer</article-title>. <source>Clin Chim Acta</source>
<volume>398</volume>: <fpage>75</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">18778699</pub-id></mixed-citation></ref><ref id="pone.0057240-CondeSnchez1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Conde-S&#x000e1;nchez</surname><given-names>M</given-names></name>, <name><surname>Rold&#x000e1;n-Fontana</surname><given-names>E</given-names></name>, <name><surname>Chueca-Porcuna</surname><given-names>N</given-names></name>, <name><surname>Pardo</surname><given-names>S</given-names></name>, <name><surname>Porras-Gracia</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>Analytical performance evaluation of a particle-enhanced turbidimetric cystatin C assay on the Roche COBAS 6000 analyzer</article-title>. <source>Clin Biochem</source>
<volume>43</volume>: <fpage>921</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">20416293</pub-id></mixed-citation></ref><ref id="pone.0057240-Flodin1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Flodin</surname><given-names>M</given-names></name>, <name><surname>Larsson</surname><given-names>A</given-names></name> (<year>2009</year>) <article-title>Performance evaluation of a particle-enhanced turbidimetric cystatin C assay on the Abbott ci8200 analyzer</article-title>. <source>Clin Biochem</source>
<volume>42</volume>: <fpage>873</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">19281807</pub-id></mixed-citation></ref><ref id="pone.0057240-Bargnoux3"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Bargnoux</surname><given-names>AS</given-names></name>, <name><surname>Servel</surname><given-names>AC</given-names></name>, <name><surname>Pi&#x000e9;roni</surname><given-names>L</given-names></name>, <name><surname>Dupuy</surname><given-names>AM</given-names></name>, <name><surname>Badiou</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Accuracy of GFR predictive equations in renal transplantation: validation of a new turbidimetric cystatin C assay on Architect c8000</article-title>. <source>Clin Biochem</source>
<volume>45</volume>: <fpage>151</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">22079396</pub-id></mixed-citation></ref><ref id="pone.0057240-Liu3"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Lv</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>C</given-names></name>, <name><surname>Shi</surname><given-names>C</given-names></name>, <name><surname>Cheng</surname><given-names>C</given-names></name> (<year>2012</year>) <article-title>Comparison of prediction equations to estimate glomerular filtration rate in Chinese patients with chronic kidney disease</article-title>. <source>Intern Med J</source>
<volume>42</volume>: <fpage>e59</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">21118405</pub-id></mixed-citation></ref><ref id="pone.0057240-Grubb1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Grubb</surname><given-names>A</given-names></name>, <name><surname>Blirup-Jensen</surname><given-names>S</given-names></name>, <name><surname>Lindstrom</surname><given-names>V</given-names></name>, <name><surname>Schmidt</surname><given-names>C</given-names></name>, <name><surname>Althaus</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>First certified reference material for Cystatin C in human serum ERM-DA471/IFCC</article-title>. <source>Clin Chem Lab Med</source>
<volume>48</volume>: <fpage>1619</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">21034257</pub-id></mixed-citation></ref><ref id="pone.0057240-Dharnidharka1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Dharnidharka</surname><given-names>VR</given-names></name>, <name><surname>Kwon</surname><given-names>C</given-names></name>, <name><surname>Stevens</surname><given-names>G</given-names></name> (<year>2002</year>) <article-title>Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis</article-title>. <source>Am J Kidney Dis</source>
<volume>40</volume>: <fpage>221</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">12148093</pub-id></mixed-citation></ref><ref id="pone.0057240-Roos2"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Roos</surname><given-names>JF</given-names></name>, <name><surname>Doust</surname><given-names>J</given-names></name>, <name><surname>Tett</surname><given-names>SE</given-names></name>, <name><surname>Kirkpatrick</surname><given-names>CM</given-names></name> (<year>2007</year>) <article-title>Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children- A meta-analysis</article-title>. <source>Clin Biochem</source>
<volume>40</volume>: <fpage>383</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">17316593</pub-id></mixed-citation></ref><ref id="pone.0057240-Stevens2"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Stevens</surname><given-names>LA</given-names></name>, <name><surname>Coresh</surname><given-names>J</given-names></name>, <name><surname>Greene</surname><given-names>T</given-names></name>, <name><surname>Levey</surname><given-names>AS</given-names></name> (<year>2006</year>) <article-title>Assessing kidney function-measured and estimated glomerular filtration rate</article-title>. <source>N Engl J Med</source>
<volume>354</volume>: <fpage>2473</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">16760447</pub-id></mixed-citation></ref><ref id="pone.0057240-Sjostrom1"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Sjostrom</surname><given-names>PA</given-names></name>, <name><surname>Jones</surname><given-names>IL</given-names></name>, <name><surname>Tidman</surname><given-names>MA</given-names></name> (<year>2009</year>) <article-title>Cystatin C as a filtration marker-haemodialysis patients expose its strengths and limitations</article-title>. <source>Scand J Clin Lab Invest</source>
<volume>69</volume>: <fpage>65</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">18728932</pub-id></mixed-citation></ref><ref id="pone.0057240-Horio1"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Horio</surname><given-names>M</given-names></name>, <name><surname>Imai</surname><given-names>E</given-names></name>, <name><surname>Yasuda</surname><given-names>Y</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Matsuo</surname><given-names>S</given-names></name> (<year>2011</year>) <article-title>Performance of serum cystatin C versus serum creatinine as a marker of glomerular filtration rate as measured by inulin renal clearance</article-title>. <source>Clin Exp Nephrol</source>
<volume>15</volume>: <fpage>868</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">21861242</pub-id></mixed-citation></ref><ref id="pone.0057240-Kotajima1"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Kotajima</surname><given-names>N</given-names></name>, <name><surname>Yanagawa</surname><given-names>Y</given-names></name>, <name><surname>Aoki</surname><given-names>T</given-names></name>, <name><surname>Tsunekawa</surname><given-names>K</given-names></name>, <name><surname>Morimura</surname><given-names>T</given-names></name> (<year>2010</year>) <article-title>Influence of thyroid hormones and transforming growth factor-b1 on cystatin C concentrations</article-title>. <source>J Int Med Res</source>
<volume>38</volume>: <fpage>1365</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">20926009</pub-id></mixed-citation></ref><ref id="pone.0057240-Fricker1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Fricker</surname><given-names>M</given-names></name>, <name><surname>Wiesli</surname><given-names>P</given-names></name>, <name><surname>Brandle</surname><given-names>M</given-names></name>, <name><surname>Schwegler</surname><given-names>B</given-names></name>, <name><surname>Schmid</surname><given-names>C</given-names></name> (<year>2003</year>) <article-title>Impact of thyroid dysfunction on serum cystatin C. Kidney Int</article-title>. <volume>63</volume>: <fpage>1944</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0057240-Rule1"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Rule</surname><given-names>AD</given-names></name>, <name><surname>Bergstralh</surname><given-names>EJ</given-names></name>, <name><surname>Slezak</surname><given-names>JM</given-names></name>, <name><surname>Bergert</surname><given-names>J</given-names></name>, <name><surname>Larson</surname><given-names>TS</given-names></name> (<year>2006</year>) <article-title>Glomerular filtration rate estimated by cystatin C among different clinical presentations</article-title>. <source>Kidney Int</source>
<volume>69</volume>: <fpage>399</fpage>&#x02013;<lpage>405</lpage>.<pub-id pub-id-type="pmid">16408133</pub-id></mixed-citation></ref><ref id="pone.0057240-Porba1"><label>51</label><mixed-citation publication-type="journal">
<name><surname>Por&#x00119;ba</surname><given-names>R</given-names></name>, <name><surname>Ga&#x00107;</surname><given-names>P</given-names></name>, <name><surname>Por&#x00119;ba</surname><given-names>M</given-names></name>, <name><surname>Antonowicz-Juchniewicz</surname><given-names>J</given-names></name>, <name><surname>Andrzejak</surname><given-names>R</given-names></name> (<year>2011</year>) <article-title>Relation between occupational exposure to lead, cadmium, arsenic and concentration of cystatin C</article-title>. <source>Toxicology</source>
<volume>283</volume>: <fpage>88</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">21356263</pub-id></mixed-citation></ref></ref-list></back></article>